Dr. Michael Atkins, MD

• Hematology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• Harvard Medical School

  2003

• New England Medical Center

  Residency Hospital, 1983

• Beth Israel Deaconess Medical Center

  Internship Hospital, 1981

• Tufts University School Of Medicine

  Medical School, 1980

• Tufts University

  Undergraduate School, 1976

• Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: Analysis from the treatment approaches in renal cancer global evaluation trial (TARGET), 2012-11-07

• Future Directions in Renal Cell Carcinoma: 2011 and Beyond, 2011-07-25

• Volume of Disease as a Predictor for Clinical Outcomes in Patients With Melanoma Brain Metastases Treated With Stereotactic Radiosurgery and Immune Checkpoint Therapy, 2022-01-12

• High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma, 2011-12-21

• Patient-Reported Outcomes in a Phase 2 Study Comparing Atezolizumab Alone or With Bevacizumab Versus Sunitinib in Previously Untreated Metastatic Renal Cell Carcinoma, 2020-04-24

• Angiogenic factor and cytokine analysis among patients treated with adjuvant VEGFR TKIs in resected renal cell carcinoma, 2019-08-30

• The State of Melanoma: Challenges and Opportunities, 2016-04-17

• Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling, 2010-08-10

• Transcriptional Profiling of Malignant Melanoma Reveals Novel and Potentially Targetable Gene Fusions, 2022-03-15

• Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma, 2009-07-29

• Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma, 2017-08-01

• Tumor Necrosis on Magnetic Resonance Imaging Correlates with Aggressive Histology and Disease Progression in Clear Cell Renal Cell Carcinoma, 2013-10-19

• A case of checkpoint inhibitor-induced celiac disease, 2019-08-05

• Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection, 2019-12-17

• Discordance between Cobas BRAF V600 testing and VE1 immunohistochemistry in a melanoma patient with bone marrow metastases, 2017-05-19

• Exceptional response and multisystem autoimmune-like toxicities associated with the same T cell clone in a patient with uveal melanoma treated with immune checkpoint inhibitors, 2019-03-04

• Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer, 2012-06-02

• Updated recommendations on the diagnosis, management, and clinical trial eligibility criteria for patients with renal medullary carcinoma, 2018-09-12

• Resistance of Renal Cell Carcinoma to Sorafenib Is Mediated by Potentially Reversible Gene Expression, 2011-04-29

• Phase II trial of temozolomide and sorafenib in advanced melanoma patients with or without brain metastases, 2009-12-15

• Innovations and Challenges in Renal Cancer: Summary Statement From the Third Cambridge Conference, 2009-05-15

• Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma, 2023-03-23

• Treatment Selection for Patients With Metastatic Renal Cell Carcinoma, 2009-05-15

• A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status, 2017-07-18

• Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer Analysis, 2021-12-03

• Rapid Development of Hypertension by Sorafenib: Toxicity or Target?, 2009-09-29

• BRAF mutations in metanephric adenoma of the kidney, 2012-06-09

• Correction: Zhang et al. Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer Analysis.Cancers2021,13, 6109, 2022-09-19

• Combination of Anti-Angiogenics and Checkpoint Inhibitors for Renal Cell Carcinoma: Is the Whole Greater Than the Sum of Its Parts?, 2022-01-27

• Defining the critical hurdles in cancer immunotherapy, 2011-12-14

• Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial, 2010-11-03

• Incidence and Durability of SARS-CoV-2 Antibodies in Patients with Cancer and Health Care Workers following the First Wave of the Pandemic, 2022-02-19

• Cardiovascular toxicity following anti-angiogenic therapy in persons over age 65 with advanced renal cell carcinoma, 2015-10-06

• The State of Melanoma: Emergent Challenges and Opportunities, 2021-01-07

• Prospective Analysis of Genetic Polymorphisms and Risk of Recurrence in Renal Cell Cancer, 2012-12-07

• The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared to Rapamycin in Renal Cell Carcinoma, 2010-07-06

• Targeting DDX3X triggers anti-tumor immunity via a dsRNA-mediated tumor-intrinsic type I interferon response, 2021-05-03